Kos Pharmaceuticals About
Kos Kos Pharmaceuticals, Inc. ("Kos" or the "Company") – named
after the Greek island where Hippocrates founded the science of medicine – is
a fully integrated specialty pharmaceutical company engaged in the development
of proprietary prescription pharmaceutical products, principally for treatment
of cardiovascular, respiratory and metabolic diseases. The Company’s principal
product development strategy is to reformulate existing pharmaceutical products
with large market potential to improve safety, effectiveness and patient compliance.
The Company is concentrating on the cardiovascular and respiratory
markets because of their extraordinary size and growth, because physician prescribing
patterns in these markets are importantly influenced by an identifiable group
of physicians that can be addressed by our relatively small specialty sales force,
and because of management's extensive experience with these markets. KOS
currently markets two proprietary innovative drugs for the treatment of cholesterol
disorders and one for asthma. Niaspan
-- NIASPAN® is the only prescription extended-release form of niacin Advicor
--cholesterol medication Azmacort
-- Inhalation Aerosol is indicated in the maintenance treatment of asthma
as prophylactic therapy Currently, three other NDA projects
are in development. KS 01-019 -- The first product, scheduled for
launch in 2007, is a dual component therapy for dyslipidemia that is expected
to be more effective in lowering LDL-C than Advicor. KS 01-018 --
Periperhal Arterial Disease (PAD) Azmacort
-- Inhalation Aerosol is indicated in the maintenance treatment of asthma
as prophylactic therapy More
on Kos